OrbiMed Royalty & Credit Opportunities Access Fund IV LP
Raised
$49M
Investors
93
Min Invest
$100,000
AltStreet Analysis
·Generated from EDGAR primary sources
OrbiMed Royalty & Credit Opportunities Access Fund IV LP is a Delaware limited partnership filing under Rule 506(b) and Section 3(c), managed by PPB OrbiMed Royalty Fund IV Mgt LLC and PPB Advisors LLC. This amended filing reports $48.6M raised from 93 investors with a $100K minimum investment. The fund operates in the digital IP royalties category.
This offering represents a relatively accessible entry point ($100K minimum) within the digital IP royalties space, which typically attracts accredited investors through 506(b) private placements. The 93-investor count suggests a retail-oriented or semi-institutional distribution model, moderately sized relative to the $48.6M raised to date.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Brendan Lake
Executive Officer · Conshohocken, PA
N/A PPB OrbiMed Royalty Fund IV Mgt LLC
Executive Officer · Conshohocken, PA
N/A PPB Advisors LLC
Executive Officer · Conshohocken, PA
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
